GSK Stock Recent News

GSK PLC (LSE:GSK, NYSE:GSK) has reached a confidential settlement regarding a lawsuit in California, which accused its discontinued heartburn medication, Zantac, of causing cancer, thus avoiding a trial scheduled for February 20. In a statement, the UK pharma giant stated the case will be dismissed, emphasizing that this settlement does not imply any admission of liability.

GSK said on Thursday it agreed to confidentially settle one more lawsuit in California that alleged its discontinued heartburn drug Zantac caused cancer, the latest in a series of settlements to end costly litigation.

GSK's revenues benefit from strong growth across all segments, especially the Shingles and RSV vaccines. The company also issues fresh 2024 guidance for all its segments.

The RSV shot, called Abrysvo, booked £1.2 billion, or $1.5 billion, in sales after only being on the market for roughly half a year.

GSK on Wednesday lifted its long-term outlook for 2026-2031 as it predicted new drug and vaccine launches will see its annual sales hit £38 billion by the start of the next decade following the blockbuster launch of its new RSV vaccine Arexvy in May 2023.

GSK PLC (LSE:GSK, NYSE:GSK) on Wednesday increased its outlook for sales out to 2031 driven by a raft of major product launches from 2025. Chief Executive Emma Walmsley said: “We are now planning for at least 12 major launches from 2025, with new Vaccines and Specialty Medicines for infectious diseases, HIV, respiratory and oncology.

GSK beat market estimates for fourth-quarter profit and sales on Wednesday, underpinned by a strong launch of its respiratory syncytial virus (RSV) vaccine Arexvy and steady demand for its shingles shot and HIV medicines.

The U.K.-based company is looking to recover after a lackluster 2023.

One of the most important sectors not only in the financial markets but also in everyone's life, is the healthcare sector. It can provide investors with good returns due to its constant growth and continuous development, and the more it grows, the more companies grow along with it.

GSK is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.